# Materia Medica Holding clinical trials: 43

ClinicalTrials.gov lists 43 trials with Materia Medica Holding as lead sponsor, 4 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Materia Medica Holding: 43 rows for $5, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/materia-medica-holding

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 4
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 10, 2026 | NCT07754279 | Clinical Trial of the Safety and Tolerability of MMH-522 in Healthy Volunteers | Materia Medica Holding | Phase 1 | Completed | Cough | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754279) |
| July 16, 2026 | NCT07708623 | Clinical Trial of the Safety and Tolerability of the Drug MMH-450 in Healthy Volunteers | Materia Medica Holding | Phase 1 | Completed | Sleep Disorders | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708623) |
| June 16, 2026 | NCT07650227 | Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of Acute Bronchitis in Adult Patients | Materia Medica Holding | Phase 3 | Recruiting | Bronchitis, Acute Bronchitis | 308 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07650227) |
| September 12, 2025 | NCT07171099 | Efficacy and Safety of Rengalin in the Treatment of ARVI Cough in Children | Materia Medica Holding | Phase 3 | Recruiting | Cough | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07171099) |
| March 28, 2025 | NCT06901297 | The Efficacy and Safety of Raphamin in the Treatment of Acute Rhinosinusitis in Adult Patients | Materia Medica Holding | Phase 3 | Recruiting | Rhinosinusitis, Rhinosinusitis Acute | 552 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06901297) |
| December 4, 2024 | NCT06715891 | Clinical Trial of the Efficacy and Safety of Raphamin in the Treatment of ARVI in Children Aged 3-12 Years | Materia Medica Holding | Phase 3 | Recruiting | Acute Respiratory Viral Infection | 374 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06715891) |
| February 28, 2024 | NCT06284265 | Clinical Trial of the Efficacy and Safety of Raphamin in Prevention of Recurrences of Chronic Bacterial Cystitis | Materia Medica Holding | Phase 3 | Active not recruiting | Cystitis Chronic, Cystitis Bacterial, Recurrence of Chronic Bacterial Cystitis | 415 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06284265) |
| February 16, 2024 | NCT06263881 | Clinical Trial of the Efficacy and Safety of Raphamin in Combined Treatment of Community-acquired Pneumonia | Materia Medica Holding | Phase 3 | Completed | Community-acquired Pneumonia, Pneumonia | 370 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06263881) |
| November 4, 2022 | NCT05605938 | Efficacy and Safety of Tenoten in the Treatment of Children With Anxiety Disorders | Materia Medica Holding | Phase 4 | Completed | Anxiety Disorder of Childhood | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05605938) |
| May 6, 2022 | NCT05364671 | Clinical Trial of Efficacy and Safety of Raphamin in the Treatment of Coronavirus Disease 2019 in Outpatients | Materia Medica Holding | Phase 3 | Completed | Coronavirus Disease 2019 (COVID-19) | 771 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05364671) |
| October 12, 2021 | NCT05074888 | Сlinical Trial of Efficacy and Safety of Prospekta in the Treatment of Post-COVID-19 Asthenia. | Materia Medica Holding | Phase 3 | Completed | Post-acute COVID-19 Syndrome | 676 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05074888) |
| October 6, 2021 | NCT05069649 | Efficacy and Safety of Ergoferon for COVID-19 Prevention During Vaccination Against SARS-CoV-2 | Materia Medica Holding | Phase 3 | Completed | Immunization Against COVID-19 | 1,057 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05069649) |
| June 9, 2021 | NCT04918771 | Clinical Study of Efficacy and Safety of Raphamin in the Treatment of ARVI in Children 12-18 Years Old | Materia Medica Holding | Phase 3 | Completed | Acute Respiratory Viral Infection | 435 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04918771) |
| September 29, 2020 | NCT04569357 | Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children | Materia Medica Holding | Phase 3 | Completed | Attention Deficit Hyperactivity Disorder | 363 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04569357) |
| September 17, 2020 | NCT04552041 | Prospekta in the Treatment of Cognitive, Behavioral and Psychiatric Disorders in Patients With Vascular Dementia. | Materia Medica Holding | Phase 3 | Completed | Vascular Dementia | 406 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04552041) |
| June 4, 2020 | NCT04413929 | Study on Safety and Effectiveness of Ergoferon in the Treatment of Flu / ARVI in Outpatients. | Materia Medica Holding | Observational | Completed | Viral Respiratory Infection | 8,411 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04413929) |
| April 30, 2020 | NCT04370028 | Study on Efficacy and Safety of Divaza in Patients With Chronic Cerebral Ischemia and Cognitive Disorders | Materia Medica Holding | Observational | Completed | Chronic Cerebral Ischemia | 2,583 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04370028) |
| March 4, 2020 | NCT04295681 | Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Cognitive Disorders | Materia Medica Holding | Phase 3 | Completed | Cognitive Disorders | 246 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04295681) |
| January 31, 2020 | NCT04250311 | Clinical Trial of Efficacy and Safety of ММН-407 in the Treatment of Influenza in Outpatient Adults | Materia Medica Holding | Phase 3 | Suspended | Influenza | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04250311) |
| January 28, 2020 | NCT04244084 | Clinical Trial of Efficacy and Safety of ММН-407 in Acute Respiratory Viral Infection | Materia Medica Holding | Phase 3 | Completed | Viral Respiratory Infection | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04244084) |
| January 24, 2019 | NCT03815292 | Clinical Trial of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Early Recovery Stage After Ischemic Stroke | Materia Medica Holding | Phase 3 | Completed | Mild Cognitive Impairment, Ischemic Stroke | 276 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03815292) |
| October 30, 2018 | NCT03725033 | Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance | Materia Medica Holding | Phase 3 | Completed | Impaired Glucose Tolerance | 538 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03725033) |
| October 16, 2018 | NCT03707912 | Clinical Trial of Efficacy and Safety of Anaferon in the Treatment of Acute Respiratory Viral Infections | Materia Medica Holding | Phase 4 | Completed | Acute Respiratory Viral Infections | 204 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03707912) |
| April 2, 2018 | NCT03485495 | Clinical Trial of Efficacy and Safety of Divaza for Adjustment of Oxidative Disorders in Patients With Cerebral Atherosclerosis | Materia Medica Holding | Phase 4 | Completed | Cerebral Atherosclerosis | 124 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03485495) |
| October 4, 2017 | NCT03301155 | Clinical Trial of Anaferon for Children Efficacy in Prevention of Influenza and Other ARVI | Materia Medica Holding | Phase 4 | Completed | Preventive Medicine | 1,036 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03301155) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 2 |
| Phase 3 | 25 |
| Phase 4 | 14 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 37 |
| Recruiting | 4 |
| Active not recruiting | 1 |
| Suspended | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Influenza, Human | 4 |
| Cough | 2 |
| Cognitive Dysfunction | 2 |
| Obesity | 2 |
| COVID-19 | 1 |
| Ischemic Stroke | 1 |
| Anxiety Disorders | 1 |
| Rhinosinusitis | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Attention Deficit Disorder with Hyperactivity | 1 |
| Diabetes Mellitus, Type 1 | 1 |
| Sleep Wake Disorders | 1 |
| Dementia, Vascular | 1 |
| Diabetes Mellitus, Type 2 | 1 |
| Prostatic Hyperplasia | 1 |
| Bronchitis | 1 |
| Glucose Intolerance | 1 |
| Post-Acute COVID-19 Syndrome | 1 |
| Dyspepsia | 1 |
| Intracranial Arteriosclerosis | 1 |
| Community-Acquired Pneumonia | 1 |
| Pneumonia | 1 |
| Respiratory Tract Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Divorce and family law firms in the United States](https://specstream.ai/data/businesses/divorce-and-family-law-firms/united-states)
- [African restaurants in the United States](https://specstream.ai/data/businesses/african-restaurants/united-states)
- [Preschools in the United States](https://specstream.ai/data/businesses/preschools/united-states)
- [Home inspectors in the United States](https://specstream.ai/data/businesses/home-inspectors/united-states)
- [Career counseling services in the United States](https://specstream.ai/data/businesses/career-counseling-services/united-states)
- [Tiling contractors in the United States](https://specstream.ai/data/businesses/tiling-contractors/united-states)
